A Retrospective Study of Capecitabine/Temozolomide (CAPTEM) Regimen in the Treatment of Metastatic Pancreatic Neuroendocrine Tumors (pNETs) after Failing Previous Therapy

Saif, Muhammad Wasif; Kaley, Kristin; Brennan, Marianne; Garcon, Marie Carmel; Rodriguez, Gladys; Rodrı́guez, Teresa

doi:10.6092/1590-8577/1589

Cited by 21 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…96 The majority of published studies included in our review confirmed the role of site origin of neoplasm in treatment response. 29 , 30 , 32 , 37 , 40 , 42 , 48 , 49 , 93 , 97 , 98 The increased pNETs chemosensitivity, that justify the most common clinical use in this site origin of tumors, is thought to be partially attributed to absent or low levels of MGMT, more commonly reported in pNETs than in non-pNETs. 28 , 29 , 93 About this hypothesis, a recent systematic review and meta-analysis suggested that in NETs MGMT status may be predictive of TEM efficacy, however remarking that the current evidence is not enough to justify a routine detection of MGMT before starting treatment in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis

Arrivi¹,

Verrico²,

Roberto³

et al. 2022

CMAR

View full text Add to dashboard Cite

Background: Retrospective studies and single center experiences suggest a role of capecitabine combined with temozolomide (CAPTEM) in neuroendocrine tumors (NENs). Methods: We performed a systematic review to assess the efficacy and safety of CAPTEM in patients affected with NENs, with the aim to better clarify the role of this regimen in the therapeutic algorithm of NENs. Results: A total of 42 articles and 1818 patients were included in our review. The overall disease control rate was 77% (range 43.5%-100%). The median progression free survival ranged from 4 to 38.5 months, while the median overall survival ranged from 8 to 103 months. Safety analysis showed an occurrence of G3-G4 toxicities in 16.4% of the entire population. The most common toxicities were hematological (27.2%), gastrointestinal (8.3%,) and cutaneous (3.2%). Conclusion:This systematic review demonstrated that CAPTEM was an effective and relatively safe treatment for patients with advanced well-moderate differentiated NENs of gastroenteropancreatic, lung and unknown origin.

show abstract

Section: Discussionmentioning

confidence: 99%

Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis

Arrivi¹,

Verrico²,

Roberto³

et al. 2022

CMAR

View full text Add to dashboard Cite

show abstract

“…Cytostatics with particular activity in PanNENs include the following: STZ, 5-fluorouracil-based chemotherapy (5-FU, CAP -capecitabine), anthracyclines (ADM -adriamycin, EPI -epirubicin), dacarbazine (DTIC), temozolomide (TEM), irinotecan (I), and platinum-based chemotherapy (OXA -oxaliplatin, CDDP -cisplatin, CBDCA -carboplatin) administered as monotherapy or in combination with other cytostatic agents [169]. The widest clinical experience is related to PanNET treatment with streptozocin and CAPTEM (capecitabine + temozolomide) [170][171][172][173][174][175][176][177][178][179].…”

Section: Chemotherapymentioning

confidence: 99%

“…The main adverse effects of CAPTEM are mucositis, neutropaenia, and thrombocytopaenia, but the treatment is well tolerated by most patients [170][171][172][173][174][175][176]179].…”

Section: Chemotherapymentioning

confidence: 99%

“…Cytostatykami wykazującymi szczególną aktywność w PanNENs są: STZ, pochodne 5-fluorouracylu [5-FU, kapecytabina (CAP)], antracykliny [adriamycyna (ADM), epirubicyna (EPI)], dakarbazyna (DTIC), temozolomid (TEM), irynotekan (I), pochodne platyny [okasaliplatyna (OXA), cisplatyna (CDDP), karboplatyna (CBDCA)] podawane w monoterapii lub w kombinacji z innymi cystostatykami [168]. Największe doświadczenia kliniczne dotyczą leczenia PanNET z wykorzystaniem streptozocyny i schematu CAPTEM (kapecytabina + temozolomid) [170][171][172][173][174][175][176][177][178][179].…”

Section: Conflict Of Interestunclassified

“…Działania niepożądane w czasie stosowania schematu CAPTEM to przede wszystkim uszkodzenie śluzówek, neutropenia i małopłytkowość, poza tym leczenie jest dobrze tolerowane przez większość chorych [170][171][172][173][174][175][176]179].…”

Section: Conflict Of Interestunclassified

See 2 more Smart Citations

Pancreatic neuroendocrine neoplasms — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne trzustki — uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)]

et al. 2022

View full text Add to dashboard Cite

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially gonoma -glucagon-producing tumour, VIPoma -vasoactive intestinal peptide (VIP) producing tumour, GHRHoma -growth hormone-releasing hormone (GHRH)-producing tumour, ACTHoma -adrenocorticotropin hormone (ACTH)-producing tumour,

show abstract

Chemotherapy in NEN: still has a role?

Espinosa-Olarte

Salvia

Riesco-Martinez

et al. 2021

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Neuroendocrine neoplasms (NENs) comprise a broad spectrum of tumors with widely variable biological and clinical behavior. Primary tumor site, extent of disease, tumor differentiation and expression of so matostatin receptors, proliferation and growth rates are the major prognostic factors that determine the therapeutic strategy. Treatment options for advanced disease have considerably expanded in recent years, particularly for well differentiated tumors (NETs). Novel drugs approved over the past decade in this context include somatostatin analogues and 177Lu-oxodotreotide for somatostatin-receptor-positive gastroenteropancreatic (GEP) NETs, sunitinib for pancreatic NETs (P-NETs), and everolimus for P-NETs and non-functioning lung or gastrointestinal NETs. Nevertheless, chemotherapy remains an essential component of the treatment armamentarium of patients with NENs, particularly of patients with P-NETs or those with bulky, symptomatic or rapidly progressive tumors (generally G3 or high-G2 NENs). In this manuscript we will comprehensively review available evidence related to the use of chemotherapy in lung and GEP NENs and will critically discuss its role in the treatment algorithm of this family of neoplasms.

show abstract

A Retrospective Study of Capecitabine/Temozolomide (CAPTEM) Regimen in the Treatment of Metastatic Pancreatic Neuroendocrine Tumors (pNETs) after Failing Previous Therapy

Cited by 21 publications

References 13 publications

Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis

Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis

Pancreatic neuroendocrine neoplasms — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne trzustki — uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynych)]

Chemotherapy in NEN: still has a role?

Contact Info

Product

Resources

About